142 related articles for article (PubMed ID: 33045304)
1. ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to γδ T cell immunotherapy.
Dutta I; Dieters-Castator D; Papatzimas JW; Medina A; Schueler J; Derksen DJ; Lajoie G; Postovit LM; Siegers GM
Cancer Lett; 2021 Jan; 496():156-168. PubMed ID: 33045304
[TBL] [Abstract][Full Text] [Related]
2. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells.
Wang B; Wang Q; Wang Z; Jiang J; Yu SC; Ping YF; Yang J; Xu SL; Ye XZ; Xu C; Yang L; Qian C; Wang JM; Cui YH; Zhang X; Bian XW
Cancer Res; 2014 Oct; 74(20):5746-57. PubMed ID: 25164008
[TBL] [Abstract][Full Text] [Related]
3. Functional Plasticity of Gamma Delta T Cells and Breast Tumor Targets in Hypoxia.
Siegers GM; Dutta I; Lai R; Postovit LM
Front Immunol; 2018; 9():1367. PubMed ID: 29963058
[TBL] [Abstract][Full Text] [Related]
4. HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.
Song KH; Choi CH; Lee HJ; Oh SJ; Woo SR; Hong SO; Noh KH; Cho H; Chung EJ; Kim JH; Chung JY; Hewitt SM; Baek S; Lee KM; Yee C; Son M; Mao CP; Wu TC; Kim TW
Cancer Res; 2017 Sep; 77(18):5039-5053. PubMed ID: 28716899
[TBL] [Abstract][Full Text] [Related]
5. Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells.
Jang GB; Hong IS; Kim RJ; Lee SY; Park SJ; Lee ES; Park JH; Yun CH; Chung JU; Lee KJ; Lee HY; Nam JS
Cancer Res; 2015 Apr; 75(8):1691-702. PubMed ID: 25660951
[TBL] [Abstract][Full Text] [Related]
6. MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.
Li M; Pan M; You C; Zhao F; Wu D; Guo M; Xu H; Shi F; Zheng D; Dou J
Breast Cancer Res; 2020 Mar; 22(1):26. PubMed ID: 32143670
[TBL] [Abstract][Full Text] [Related]
7. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.
Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X
Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543
[TBL] [Abstract][Full Text] [Related]
8. EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells.
Dillard C; Kiyohara M; Mah V; McDermott SP; Bazzoun D; Tsui J; Chan AM; Haddad G; Pellegrini M; Chang YL; Elshimali Y; Wu Y; Vadgama JV; Kim SR; Goodglick L; Law SM; Patel DD; Dhawan P; O'Brien NA; Gordon LK; Braun J; Lazar G; Wicha MS; Wadehra M
Mol Cancer Ther; 2020 Aug; 19(8):1682-1695. PubMed ID: 32451329
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy.
Todaro M; Turdo A; Bartucci M; Iovino F; Dattilo R; Biffoni M; Stassi G; Federici G; De Maria R; Zeuner A
Cancer Res; 2013 Nov; 73(21):6393-400. PubMed ID: 24008319
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
11. Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.
Hu Y; Yagüe E; Zhao J; Wang L; Bai J; Yang Q; Pan T; Zhao H; Liu J; Zhang J
Cancer Lett; 2018 Jun; 423():47-59. PubMed ID: 29496539
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3.
Rau A; Lieb WS; Seifert O; Honer J; Birnstock D; Richter F; Aschmoneit N; Olayioye MA; Kontermann RE
Mol Cancer Ther; 2020 Jul; 19(7):1474-1485. PubMed ID: 32430487
[TBL] [Abstract][Full Text] [Related]
13. Determination of the target proteins in chemotherapy resistant breast cancer stem cell-like cells by protein array.
Kars MD; Yıldırım G
Eur J Pharmacol; 2019 Apr; 848():23-29. PubMed ID: 30707960
[TBL] [Abstract][Full Text] [Related]
14. Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3.
Thomas ML; de Antueno R; Coyle KM; Sultan M; Cruickshank BM; Giacomantonio MA; Giacomantonio CA; Duncan R; Marcato P
Mol Oncol; 2016 Nov; 10(9):1485-1496. PubMed ID: 27592281
[TBL] [Abstract][Full Text] [Related]
15. PGE
Lin MC; Chen SY; He PL; Herschman H; Li HJ
Int J Cancer; 2018 Sep; 143(6):1440-1455. PubMed ID: 29658109
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract][Full Text] [Related]
17. Autophagy Differentially Regulates Distinct Breast Cancer Stem-like Cells in Murine Models via EGFR/Stat3 and Tgfβ/Smad Signaling.
Yeo SK; Wen J; Chen S; Guan JL
Cancer Res; 2016 Jun; 76(11):3397-410. PubMed ID: 27197172
[TBL] [Abstract][Full Text] [Related]
18. Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia.
Peng F; Wang JH; Fan WJ; Meng YT; Li MM; Li TT; Cui B; Wang HF; Zhao Y; An F; Guo T; Liu XF; Zhang L; Lv L; Lv DK; Xu LZ; Xie JJ; Lin WX; Lam EW; Xu J; Liu Q
Oncogene; 2018 Feb; 37(8):1062-1074. PubMed ID: 29106390
[TBL] [Abstract][Full Text] [Related]
19. Role of Krüppel-like Factor 4-p21
Kim SH; Singh SV
Cancer Prev Res (Phila); 2019 Mar; 12(3):125-134. PubMed ID: 30723175
[TBL] [Abstract][Full Text] [Related]
20. A novel miR-34a target, protein kinase D1, stimulates cancer stemness and drug resistance through GSK3/β-catenin signaling in breast cancer.
Kim do Y; Park EY; Chang E; Kang HG; Koo Y; Lee EJ; Ko JY; Kong HK; Chun KH; Park JH
Oncotarget; 2016 Mar; 7(12):14791-802. PubMed ID: 26895471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
